Biotech in Belgium: news and updates

Latest Posts

News and Trends 25 Oct 2014

Belgian Promethera received approval to start World first Phase IIb/III stem-cell based urea cycle disorders treatment

Promethera is a promising Belgian Biotechnology company developing stem-cell based treatment against liver diseases. It was created in 2009, counts 44 employees and has raised €39M. The company now moves to another level by starting its own Phase IIb/III to treat paediatric patients with urea cycle disorders. It is the first company in the World […]

October 25, 2014 - 1 minutemin - By Philip Hemme

News and Trends 22 Oct 2014

New Treatment against critic Leukemia Approved In Europe

Janssen’s Imbruvica (ibrutinib), the once-daily oral Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Europe as a treatment for two blood cancers. The drug has been ratified by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia. The therapy functions block BTK, a protein that […]

October 22, 2014 - 2 minutesmins - By Julie Lellouche

10486567 10152342154846513 5707030158597204448 o

News and Trends 18 Oct 2014

One Week European Biotech Industry Celebration

The European Biotech Week was celebrated for the second time at the beggining of October. It was an important event to discuss and develop biotechnology in Europe. The European Biotech Week was organized by EuropaBio, european organization for Biotech companies. It was also an opportunity to bring together biotech associations because they are key in helping to […]

October 18, 2014 - 1 minutemin - By Julie Lellouche

News and Trends 11 Oct 2014

ARTES Biotechnology, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary applications. Nowadays virus-like particles (VLPs) have become a widely used vehicle for the development of vaccines used in humans. Without being infectious, the particles are used to transport foreign antigens in an ideal way to the immune system. For veterinary applications, the applied VLP production […]

October 11, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 29 Sep 2014

How to Save Thousands of Lives Thanks to Tuberculosis Test Fitting in your Pocket?

The EU-funded POCKET project is developing a low-cost urine test that can quickly detect tuberculosis (TB), a preventable disease that kills nearly 2 million people every year. Started in November 2013, the initiative already started and develops a low-cost urine test that will make TB detection accessible to all. Right now, researchers working on POCKET […]

September 29, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 19 Aug 2014

Ablynx gain €2.1m to develop a novel Nanobodies for Ocular applications

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Ablynx today announced that it has been awarded a €2.1 million grant by the Flemish Agency for […]

August 19, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 19 Aug 2014

GSK abandon its joint drug project with Galapagos

According to Reuters, Galapagos, a Belgian biotech group announced that GlaxoSmithKline has stopped a joint drug development project over concerns about adverse effects. In June 2006, Galapagos signed a broad alliance with GSK to discover and develop breakthrough medicines. This multi-target, multi-year alliance runs from target discovery through to delivery of a clinical Proof of Concept. […]

August 19, 2014 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us